BioMotiv is a mission-aligned partner of Harrington Discovery Institute, established under The Harrington Project for Discovery & Development in 2012. BioMotiv aligns drug development expertise, capital, and pharmaceutical partners to accelerate discoveries into medicines.
In 2021, the Journal of Commercial Biotechnology recognized BioMotiv as one of the top two innovative organizations in their External Innovators category.
Allinaire Therapeutics, a BioMotiv portfolio company, is advancing a novel treatment for pulmonary arterial hypertension (PAH). In 2022, the international research-focused pharmaceutical and healthcare group, Chiesi Farmaceutici S.p.A., acquired the worldwide rights to a portfolio of therapeutics from Allinaire for the potential treatment of PAH.
“We are grateful to Harrington Discovery Institute and BioMotiv for their support. Without it we wouldn’t have been able to get this far.”
IRINA PETRACHE, MD, Chief of Pulmonary, Critical Care, and Sleep Medicine, National Jewish Health